National University of Singapore

First made-in-Singapore cancer drug enters clinical testing

Thursday, July 23, 2015

A made-in-Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore’s biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. The Agency for Science, Technology and Research (A*STAR) and Duke-National University of Singapore Graduate Medical School (Duke-NUS) have announced the start of a phase I clinical trial of novel cancer drug candidate, ETC-159.

[Read More]

PAREXEL Academy expands to Singapore

Tuesday, October 11, 2011

PAREXEL Academy, a provider of education and professional training for the biopharmaceutical industry in the field of clinical research, which is operated by PAREXEL International, has entered into an agreement with the National University of Singapore (NUS), through its National University of Singapore Academy of GxP Excellence (NUSAGE), to offer an academic program in Singapore to help meet the increasing demand for talent in the field of clinical research in the Asia region. This demand is being driven by the growing complexity and globalization of biopharmaceutical research and development.

[Read More]